Mark Yeo1, Yoshio Masuda1, Mikel-Prieto Calvo2, Marcello Di Martino3, Benedetto Ielpo4,5, Koh Ye-Xin6,7. 1. Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 2. Hepatobiliary Surgery and Liver Transplantation Unit, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, University of the Basque Country, Bilbao, Spain. 3. Department of Hepatobiliary and Liver Transplant Surgery, A.O.R.N. Cardarelli, Naples, Italy. 4. Hepatopancreatobiliary Unit, Parc Salut Mar University Hospital, Barcelona, Spain. 5. Pompeu Fabra University, Barcelona, Spain. 6. Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, 1 Outram Road, Singapore, 169608, Singapore. koh.ye.xin@singhealth.com.sg. 7. Duke-National University of Singapore Medical School, Singapore, Singapore. koh.ye.xin@singhealth.com.sg.
Abstract
BACKGROUND: Historically , liver metastases due to melanoma have been associated with dismal prognosis. Moreover, the actual survival benefit from the treatment of melanoma liver metastases is still controversial. Hence, this study aims to evaluate the difference in surgical versus non-surgical options for melanoma liver metastases. METHODS: Four databases (PubMed, EMBASE, Scopus, and Cochrane Library) were searched from inception to July 17, 2022. Studies were included if they compared outcomes between surgical and non-surgical treatment for patients with liver metastases from resectable melanoma. Meta-analyses were performed for the outcomes of 1-year, 2-year, 3-year and 5-year OS. Sensitivity analyses were performed for outcomes with substantial statistical heterogeneity. To account for possible moderators that might contribute to statistical heterogeneity, univariate meta-regression with mixed-effects models and subgroup analyses were conducted for the outcome of 2-year OS. RESULTS: The search yielded 6610 articles; 13 studies were included in our analysis. Meta-analyses showed that survival outcomes were in favour of patients undergoing surgery as compared to non-surgery: 1-year OS (HR = 0.29, 95%CI 0.19-0.44, p < 0.00001), 2-year OS (HR = 0.19, 95%CI 0.09-0.38, p < 0.00001), 3-year OS (HR = 0.07, 95%CI 0.03-0.19, p < 0.00001) and 5-year OS (HR = 0.07, 95%CI 0.02-0.22, p < 0.00001). All included studies were of high quality. There was moderate-to-high statistical heterogeneity. Findings were robust to sensitivity analyses. Subgroup analyses and univariate meta-regression revealed neoadjuvant therapy and age as statistically significant subgroup and moderator respectively. CONCLUSIONS: This study suggests that surgical treatment of melanoma liver metastases could offer better OS outcomes compared with non-surgical treatment.
BACKGROUND: Historically , liver metastases due to melanoma have been associated with dismal prognosis. Moreover, the actual survival benefit from the treatment of melanoma liver metastases is still controversial. Hence, this study aims to evaluate the difference in surgical versus non-surgical options for melanoma liver metastases. METHODS: Four databases (PubMed, EMBASE, Scopus, and Cochrane Library) were searched from inception to July 17, 2022. Studies were included if they compared outcomes between surgical and non-surgical treatment for patients with liver metastases from resectable melanoma. Meta-analyses were performed for the outcomes of 1-year, 2-year, 3-year and 5-year OS. Sensitivity analyses were performed for outcomes with substantial statistical heterogeneity. To account for possible moderators that might contribute to statistical heterogeneity, univariate meta-regression with mixed-effects models and subgroup analyses were conducted for the outcome of 2-year OS. RESULTS: The search yielded 6610 articles; 13 studies were included in our analysis. Meta-analyses showed that survival outcomes were in favour of patients undergoing surgery as compared to non-surgery: 1-year OS (HR = 0.29, 95%CI 0.19-0.44, p < 0.00001), 2-year OS (HR = 0.19, 95%CI 0.09-0.38, p < 0.00001), 3-year OS (HR = 0.07, 95%CI 0.03-0.19, p < 0.00001) and 5-year OS (HR = 0.07, 95%CI 0.02-0.22, p < 0.00001). All included studies were of high quality. There was moderate-to-high statistical heterogeneity. Findings were robust to sensitivity analyses. Subgroup analyses and univariate meta-regression revealed neoadjuvant therapy and age as statistically significant subgroup and moderator respectively. CONCLUSIONS: This study suggests that surgical treatment of melanoma liver metastases could offer better OS outcomes compared with non-surgical treatment.
Authors: J-M Aubin; J Rekman; F Vandenbroucke-Menu; R Lapointe; R J Fairfull-Smith; R Mimeault; F K Balaa; G Martel Journal: Br J Surg Date: 2013-06-17 Impact factor: 6.939
Authors: Ryan T Groeschl; Ido Nachmany; Jennifer L Steel; Srinevas K Reddy; Evan S Glazer; Mechteld C de Jong; Timothy M Pawlik; David A Geller; Allan Tsung; J Wallis Marsh; Bryan M Clary; Steven A Curley; T Clark Gamblin Journal: J Am Coll Surg Date: 2012-03-16 Impact factor: 6.113
Authors: Samantha R Horn; Kelsey C Stoltzfus; Eric J Lehrer; Laura A Dawson; Leila Tchelebi; Niraj J Gusani; Navesh K Sharma; Hanbo Chen; Daniel M Trifiletti; Nicholas G Zaorsky Journal: Cancer Epidemiol Date: 2020-06-17 Impact factor: 2.984
Authors: René Adam; Laurence Chiche; Thomas Aloia; Dominique Elias; Rémy Salmon; Michel Rivoire; Daniel Jaeck; Jean Saric; Yves Patrice Le Treut; Jacques Belghiti; Georges Mantion; Gilles Mentha Journal: Ann Surg Date: 2006-10 Impact factor: 12.969
Authors: M L Elias; S Behbahani; S Maddukuri; A M John; R A Schwartz; W C Lambert Journal: J Eur Acad Dermatol Venereol Date: 2019-06-03 Impact factor: 6.166
Authors: Eric Van Cutsem; Bernard Nordlinger; Rene Adam; Claus-Henning Köhne; Carmelo Pozzo; Graeme Poston; Marc Ychou; Philippe Rougier Journal: Eur J Cancer Date: 2006-08-10 Impact factor: 9.162
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Date: 2008-03-22 Impact factor: 79.321